A clinical study of the HIV-1 protease inhibitor, 141W94 (VX-478) to evaluate a new soft gelatin capsule formulation and to determine the effects of food upon bioavailability: WT Symonds1, BM Sadler1, GE Chittick1, J Moss2. Glaxo Wellcome Research and Development, 1RTP, NC, USA and 2Greenford, Middlesex, UK